Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Staphylococcus aureus | Peptide deformylase | Starlite/ChEMBL | References |
Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4) | Peptide deformylase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma cruzi | hypothetical protein | Peptide deformylase | 183 aa | 155 aa | 22.6 % |
Trichomonas vaginalis | abca6, putative | Peptide deformylase | 183 aa | 162 aa | 25.3 % |
Loa Loa (eye worm) | adipor-like receptor | Peptide deformylase | 203 aa | 163 aa | 23.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0108 | 0.0708 | 0.1603 |
Schistosoma mansoni | P2X receptor subunit | 0.0543 | 0.9693 | 1 |
Schistosoma mansoni | P2X receptor subunit | 0.0543 | 0.9693 | 1 |
Schistosoma mansoni | P2X receptor subunit | 0.0543 | 0.9693 | 1 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.0543 | 0.9693 | 1 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.0543 | 0.9693 | 1 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.0543 | 0.9693 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0108 | 0.0708 | 0.1603 |
Plasmodium vivax | peptide deformylase, putative | 0.0558 | 1 | 0.5 |
Mycobacterium leprae | PROBABLE POLYPEPTIDE DEFORMYLASE DEF (PDF) (FORMYLMETHIONINE DEFORMYLASE) | 0.0558 | 1 | 0.5 |
Mycobacterium ulcerans | peptide deformylase | 0.0558 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0288 | 0.4416 | 1 |
Mycobacterium tuberculosis | Probable polypeptide deformylase Def (PDF) (formylmethionine deformylase) | 0.0558 | 1 | 1 |
Trypanosoma brucei | Polypeptide deformylase 1 | 0.0213 | 0.287 | 0.5 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0213 | 0.287 | 0.5 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0213 | 0.287 | 0.5 |
Trypanosoma brucei | Peptide deformylase 2 | 0.0213 | 0.287 | 0.5 |
Treponema pallidum | polypeptide deformylase (def) | 0.0558 | 1 | 0.5 |
Plasmodium falciparum | peptide deformylase | 0.0558 | 1 | 0.5 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.0543 | 0.9693 | 1 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0288 | 0.4416 | 1 |
Leishmania major | polypeptide deformylase-like protein, putative | 0.0213 | 0.287 | 0.5 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.0543 | 0.9693 | 1 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.0543 | 0.9693 | 1 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0213 | 0.287 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | peptide deformylase | 0.0558 | 1 | 0.5 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0213 | 0.287 | 0.5 |
Toxoplasma gondii | hypothetical protein | 0.0558 | 1 | 0.5 |
Schistosoma mansoni | P2X receptor subunit | 0.0543 | 0.9693 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.52 nM | Inhibition of Streptococcus pneumoniae PDF assessed as formate release from fMAS peptide substrate after 20 mins by formate dehydrogenase coupled assay | ChEMBL. | 22579486 |
IC50 (binding) | = 3.4 nM | Inhibition of Staphylococcus aureus PDF assessed as formate release from fMAS peptide substrate after 20 mins by formate dehydrogenase coupled assay | ChEMBL. | 22579486 |
Stability (ADMET) | = 52 % | Metabolic stability of the compound in human blood assessed as compound remaining at 2000 ng/mL after 2 hrs | ChEMBL. | 22579486 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.